drugset / Trial / NCT04417621

Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

NCT04417621

Phase 2 Active not recruiting 134 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary purpose of this study is to evaluate the efficacy of LXH254 combinations in previously treated unresectable or metastatic melanoma

Timeline

Start
2020-10-30
Primary completion
2027-02-02
Completion
2027-02-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Naporafenib Small molecule Oral
Subject Ribociclib Small molecule Oral
Subject Rineterkib Small molecule Oral
Subject Trametinib Small molecule Oral

Indications